Articles related to HEAD & NECK CANCER (HNC)
FDA Approves Toripalimab Plus Chemo for Nasopharyngeal Carcinoma
The FDA’s recent approval of toripalimab, based on the JUPITER-02 and POLARIS-02 clinical trials, marks a significant milestone in the treatment of nasopharyngeal carcinoma. With a median progression-free survival of 11.7 months, toripalimab has shown promising results in improving patient outcomes.
Oncology, Medical November 6th 2023
Head and Neck Cancer Diagnostic Delays Linked to Antibiotics Despite Clinical Practice Guidelines
Learn more about the alarming trend of diagnostic delays in head and neck cancer patients due to inappropriate antibiotic prescribing, and why adhering to current clinical guidelines is more crucial than ever.
Oncology, Medical September 11th 2023
Can Engaging in Oral Sex Increase Your Risk of Head and Neck Cancer?
The rise in oropharyngeal cancer rates, linked to high-risk HPV strains transmitted through oral sex, underscores the need for healthcare providers to promote safe sex practices, HPV vaccination, and early symptom recognition.
Oncology, Medical August 7th 2023
Plasma Epstein–Barr Virus DNA and Risk of Future Nasopharyngeal Cancer
Explore how the persistence of detectable Epstein-Barr virus DNA can serve as a significant predictive marker for nasopharyngeal cancer, potentially revolutionizing early diagnosis and improving survival rates.
Oncology, Medical July 3rd 2023